anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A missense mutation in the transcription repressor Nucleus accumbens-associated 1 (NACC1) gene at c.892C>T (p.Arg298Trp) on chromosome 19 causes severe neurodevelopmental delay ( Schoch et al., 2017). To model this disorder, we engineered the first mouse model with the homologous mutation (Nacc1+/R284W ) and examined mice from E17.5 to 8 months. Both genders had delayed weight gain, epileptiform discharges and altered power spectral distribution in cortical electroencephalogram, behavioral seizures, and marked hindlimb clasping; females displayed thigmotaxis in an open field. In the cortex, NACC1 long isoform, which harbors the mutation, increased from 3 to 6 months, whereas the short isoform, which is not present in humans and lacks aaR284 in mice, rose steadily from postnatal day (P) 7. Nuclear NACC1 immunoreactivity increased in cortical pyramidal neurons and parvalbumin containing interneurons but not in nuclei of astrocytes or oligodendroglia. Glial fibrillary acidic protein staining in astrocytic processes was diminished. RNA-seq of P14 mutant mice cortex revealed over 1,000 differentially expressed genes (DEGs). Glial transcripts were downregulated and synaptic genes upregulated. Top gene ontology terms from upregulated DEGs relate to postsynapse and ion channel function, while downregulated DEGs enriched for terms relating to metabolic function, mitochondria, and ribosomes. Levels of synaptic proteins were changed, but number and length of synaptic contacts were unaltered at 3 months. Homozygosity worsened some phenotypes including postnatal survival, weight gain delay, and increase in nuclear NACC1. This mouse model simulates a rare form of autism and will be indispensable for assessing pathophysiology and targets for therapeutic intervention.
Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of bromelain that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained. After a 1 week washout period, they received the placebo rinse (powdered sugar), following the same protocol and series of intraoral photographs.
An aqueous extract of Lawsonia inermis comprising forming an extraction from 1% to 20% of dried Lawsonia inermis leaves with water. The antibiotics polymyxin B, clindamycin, and gentamycin are each added to the water before or after extraction in the amount of 0.001% to 0.003%. After forming the aqueous extract of Lawsonia inermis, it has no antibiotic activity and the antibiotics are not detectable by chemical analysis. The aqueous extract of Lawsonia inermis is stable for at least 28 days for the topical treatment of wounds and has been stable up to two years in clinical testing. The aqueous extract of Lawsonia inermis extract is applied with a spray to the surface of the wound, followed by the application of an extract-soaked gauze dressing to the surface of the wound. The extract is effective on various types of wounds and also in healing wounds in patients who are not healing with traditional therapies.
Dual blockade of the renin-angiotensin-aldosterone system (RAS) with angiotensin blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and renal impairment. The ONTARGET trial enrolled 25,620 patients ≥55 years old with atherosclerotic disease or diabetes with end-organ damage, randomizing them to telmisartan (ARB) only, ramipril (ACE inhibitor) only, or the combination, and followed them for a median of 56 months. Patients who received the combination of ARB and ACE inhibitor did not obtain any additional benefit (no additional reduction of risk of cardiovascular death, myocardial infarction, stroke, or hospitalization from heart failure) compared to ARB monotherapy or ACE inhibitor monotherapy, but experienced an increased incidence of renal dysfunction (e.g., acute renal failure) compared with monotherapy groups.

In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on telmisartan and hydrochlorothiazide tablets and other agents that affect the RAS.

Do not co-administer aliskiren with telmisartan and hydrochlorothiazide tablets in patients with diabetes. Avoid concomitant use of aliskiren with telmisartan and hydrochlorothiazide tablets in patients with renal impairment (GFR <60 mL/min/1.73 m2).
Participants received 1 single 20 min session of sham tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of anodal tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
Gliomas are the most frequent primary neoplasm in the CNS and according to the World Health Organization histologically categorized into low-grade glioma (LGG) (WHO grades I/II) or high-grade glioma (HGG) (WHO grades III/IV). Gliomas are among the biggest challenges within the field of neuro-rehabilitation and oncology, and optimising treatment by improving QoL, function and cognition is of major clinical importance in this population. Because the majority of patients cannot be cured, clinical cancer research traditionally have focused on prolonging survival, exposing relapse or optimising the response to the medical treatment. Today there is a general consensus that health-related quality of life (HRQoL) is important in the evaluation of new treatments. However, research in HRQoL among patients with gliomas is scarce compared to the other categories of patients with tumors. In recent years have exercise become an important part of cancer treatment. The effects is well documented in studies among other cancer patients than gliomas and includes improvements of quality of life, physical function, reduce fatigue and thereby supports daily activities among cancer patients'. Inpatient rehabilitation studies among glioma patients have also indicated improved HRQoL and functional measurements such as activity of daily life, mobility and cognition. Despite of this rehabilitation efforts is still not emphasized in this population and recent literature concludes that there are no well-designed clinical studies examining the effect of multidisciplinary rehabilitation among Glioma patients. This study is the first to investigate the effect of an intensive specialised interdisciplinary outpatient rehabilitation program among gliomas patients.
<P>PROBLEM TO BE SOLVED: To obtain a composition, especially food and beverage that are safe to human, animals, etc., is continuously ingested and has excellent prevention and/or amelioration action on peptic ulcer.  <P>SOLUTION: The composition for preventing and/or ameliorating peptic ulcer comprises a sesamin. The composition contains 0.001-10 wt.% of a sesamin. An excellent peptic amelioration composition, especially food and beverage are obtained. The composition containing a sesamin is safely administered to human and animals. Consequently, the composition is continuously administered and is a composition for preventing and ameliorating peptic ulcer without causing a rebound.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Despite the high prevalence of sleep disturbance in the heart failure population, information about its consequence on daytime function in patients with left-ventricular assist devices (LVADs) is limited. This study examined the nighttime and daytime sleep patterns and changes from pre-implant to 6 months post-implant. This study included 32 LVAD patients. Demographics, nighttime and daytime sleep variables were collected pre-implant and at 1, 3, and 6 months post-implant. Wrist actigraphy and self-report questionnaires measured objective and subjective sleep, respectively. Objective nighttime sleep data were sleep efficiency (SE), sleep latency (SL), total sleep time (TST), wake after sleep onset (WASO), and sleep fragmentation (SF). Objective daytime sleep data were nap times. Self-reported Subjective Sleep Quality Scale (SSQS) and Stanford Sleepiness Scale (SSS) were subjective measures. Increased SF and WASO scores and decreased TST and SE scores were found pre-LVAD implant, indicative of poor sleep quality. TST, SE, naptime and SSQS scores were higher at 3 and 6 months post-implant compared to baseline. Decreases in TST and SF scores were observed at 3 and 6 months post-implant along with increases in SSS scores. Increasing SSS scores and decreasing overall scores from pre- and up to 6 months post-implant suggest improvement in daytime function. This study provides information on sleep-daytime function in the LVAD patient population. Improvements in daytime sleepiness do not imply "good" sleep quality, consistent with the extant knowledge in LVAD literature. Future investigations should elucidate the mechanism by which sleep-daytime function influences quality of life.
PURPOSE:To prolong the preserving period of blood, by compounding an antihemolytic agent composed of a triglyceride compound represented by a specific formula and other blood preserving liquid component to impart preservability and safety. CONSTITUTION:The title composition is prepared by dispersing and compounding a triglyceride compound represented by formula (wherein R<1>, R<2> and R<3> are respectively a 1-20C aliphatic hydrocarbon group and the sum of the carbon atoms. thereof is 10-36 and either one of them is set to a branch structure to hold red corpuscle protecting action and antihemolytic effect) in an emulsion form using a surfactant exerting no adverse effect on blood components. The triglyceride compound is compounded so that the final concn. thereof in blood to be preserved becomes 10muM-10mM. Therefore, the greater part of the red corpuscle can be held to the same state as that immediately after the collection of blood for a long period of time.
Undifferentiated embryonal sarcoma of the liver (UESL) is an extremely rare and aggressive malignancy in adults.1 Adults with UESL have a worse prognosis compared to pediatric population.2 Due to the rarity of this disease in adults, there has been a lack of information that assists in treatment decisions within this group. Improved understanding of UESL in adults might assist in understanding biological differences compared to pediatric cohorts as well as tailor treatments to improve their overall outcome. We described the management and outcome of a young adult managed at our center with metastatic relapsed UESL. For comparison, a PubMed search for adolescent and young adult (AYA) and adults with UESL was performed with the aim to review and address any distinct clinical features, different aspects of management and survival outcomes within this population. A 21-year-old male underwent right hepatectomy for a large 16 cm localized UESL with clear surgical margin and did not receive adjuvant chemotherapy. Seven months postsurgery, he relapsed with both local and metastatic disease and underwent chemotherapy with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide achieving a complete metabolic response. This was followed by Stereotactic Ablative Radiation Therapy and surgical resection of residual disease. He remains free of disease 3 years since his diagnosis. We subsequently reviewed 42 AYA and adults (aged >15) with UESL (median age, 33 years) between 1991 and 2022. Most patients presented with localized UESL and for those treated with surgery alone, 67% developed recurrences. Those receiving multimodality treatment, better outcomes, and reduced relapse rate was achieved. Twenty-seven patients developed recurrences, 13 with local recurrences and 14 with metastatic relapse. The median time to relapse was 12 months. We reported a successful outcome in multimodality treatment which resulted in long remission in a young adult with relapsed UESL. Combination of perioperative chemotherapy with locoregional treatment is important to improve long-term survival in adults with metastatic UESL.
During alcohol cue exposure, an active tDCS with a duration of 15 minutes and 2 mA is applied to the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2).
FIELD: production of pharmaceutical compositions, medicine. SUBSTANCE: novel derivatives of 1,4-dihydropyridine have common formula given in specification where R 1  is nitro- or trifluoromethyl, chlorine or atoms of chlorine in 2- and 3-positions, R 2  is saturated C 1 -C 8  alkyl having straight or branched chain or W-OZ group where W is straight C 1 -C 3 -alkylene, Z is n-C 1 -C 3 -alkyl, R 3  is methyl or ethyl, n=1-3. Some of proposed compounds possess vasodilator action and therefore they may be used in therapy of hypertension. Some of proposed compounds have vasoconstrictor action and therefore they may be used for treatment of low blood pressure. EFFECT: improved treatment of hypertension and low blood pressure. 5 cl, 4 tbl
The aggregation of α-synuclein (αS) plays a key role in Parkinson's disease (PD) etiology. While the onset of PD is age-related, the cellular quality control system appears to regulate αS aggregation throughout most human life. Intriguingly, the protein 14-3-3τ has been demonstrated to delay αS aggregation and the onset of PD in various models. However, the molecular mechanisms behind this delay remain elusive. Our study confirms the delay in αS aggregation by 14-3-3τ, unveiling a concentration-dependent relation. Utilizing microscale thermophoresis (MST) and single-molecule burst analysis, we quantified the early αS multimers and concluded that these multimers exhibit properties that classify them as nanoscale condensates that form in a cooperative process, preceding the critical nucleus for fibril formation. Significantly, the αS multimer formation mechanism changes dramatically in the presence of scaffold protein 14-3-3τ. Our data modeling suggests that 14-3-3τ modulates the multimerization process, leading to the creation of mixed multimers or co-condensates, comprising both αS and 14-3-3τ. These mixed multimers form in a noncooperative process. They are smaller, more numerous, and distinctively not on the pathway to amyloid formation. Importantly, 14-3-3τ thus acts in the very early stage of αS multimerization, ensuring that αS does not aggregate but remains soluble and functional. This offers long-sought novel entries for the pharmacological modulation of PD.
Porcine deltacoronavirus (PDCoV) infection in piglets can cause small intestinal epithelial necrosis and atrophic enteritis, which leads to severe damages to host cells, and result in diarrhea. In this study, we investigated the relationship between miR-361, SLC9A3(Solute carrier family 9, subfamily A, member 3), and NHE3(sodium-hydrogen exchanger member 3) in in porcine intestinal epithelial cells (IPI-2I) cells after PDCoV infection. Our results showed that the ssc-miR-361-3p expression inhibits the mRNA level of SLC9A3 gene which lead to the descending of NHE3 protein expression, and the NHE3 activity was suppressed. NHE3 activity was suppressed via down-regulation expression of SLC9A3 mRNA by transfection with siRNA. Ssc-miR-361-3p mimics and inhibitors were used to change the expression of ssc-miR-361-3p in IPI-2I cells. Ssc-miR-361-3p overexpression reduced the mRNA level of SLC9A3 gene, the level of NHE3 protein expression and NHE3 activity in IPI-2I cells, while ssc-miR-361-3p inhibits NHE3. Furthermore, luciferase reporter assay showed that SLC9A3 gene was a direct target of ssc-miR-361-3p. Ssc-miR-361-3p inhibition restored NHE3 activity in PDCoV infected IPI-2I cells by up-regulating SLC9A3 mRNA expression and NHE3 protein expression. These results demonstrate that the PDCoV infection can inhibit NHE3 activity through miR-361-3p/SLC9A3 regulatory axis. The relevant research is reported for the first time in PDCoV, which has significance in exploring the pathogenic mechanism of PDCoV and can provide a theoretical basis for its prevention and control. suggesting that NHE3 and ssc-miR-361-3p may be potential therapeutic targets for diarrhea in infected piglets.
Part B: A dose selected from Part A that was well tolerated will be used to check if there is a difference in the pharmacokinetics (blood levels) of the study drug when taken without food in liquid form, or as a capsule, or as a capsule together with a high fat meal to assess the effect of food. One group of 12 healthy male or female volunteers will be enrolled.
PURPOSE: To obtain a preparation consisting of a mixture of rapid-release granules and controlled release granules, capable of rapidly attaining the active ingredient blood level necessary for manifesting therapeutic effect and maintaining the blood level over a long time, and suitable for administration once a day. CONSTITUTION: This preparation for oral use contains as active ingredient a medicinal agent selected from nonsteroidal antiinflammatory agents, bronchodilators, vasodilators, cardiovascular relaxants and muscular relaxants, being composed of rapid-release granules containing 15-85wt.% of the total active ingredient and controlled release granules containing 15-85wt.% of the total active ingredient. It is preferable that the rapid-release granules comprises 45-90wt.% of the active ingredient, 2-20wt/% of a binder (e.g. lactose), 5-40wt.% of a disintegrant (e.g. corn starch) and 1wt.% of a lubricant (e.g. magnesium stearate); while the controlled release granules comprises 40-60wt.% of the active ingredient and 40-60wt.% of a retarder (e.g. ethyl cellulose, hydrogenated castor oil).
Per/polyfluoroalkyl substances (PFASs) are ubiquitous, bioaccumulative, and recalcitrant contaminants, posing global exposure and health risks. The effects of chemical structures on toxicities and the mechanisms of their obesogenic effects were largely unclear. This study used the model organism Caenorhabditis elegans to assess the impact of long-term exposure to different PFASs (PFNA, PFOSA, PFBS, PFHxS, 6:2 FTS, 4:2 FTS, PFOA, and PFOS) on growth and lipid metabolism and discussed the obesogenic mechanisms of selected PFASs. The growth assays indicated longer carbon-fluorine (-CF) chains and total fluorine atoms increased developmental toxicity of PFASs, while at 8 -CF chain-length, PFNA (-COOH terminal), PFOS (-SO3 terminal), and PFOSA (-SO2NH2 terminal) exhibited differential growth inhibition. With the toxicity ranking of PFNA > PFOS > PFOSA, all PFASs significantly induced total lipid accumulation and perturbed the lipid composition in C. elegans. All three PFASs significantly induced lipogenesis gene expression and partially suppressed lipolysis genes. The results suggested that the disruption of lipid metabolism of PFOSA depends on sbp-1, while PFNA and PFOS depend on nhr-49. In conclusion, long-term exposure to PFNA, PFOSA, and PFOS triggers obesogenic effects in organisms by distinct molecular mechanisms.
Warm gel pad application group: Gel pads kept at room temperature will be applied to the drain area of the pediatric patient whose surgical drain indication is decided to end, in a sheath designed to wrap around the drain. After waiting for 10 minutes in the application area, the drainage system will be removed by the physician.
Methods, and devices are provided for at least reducing the mineral content of a vascular calcified lesion (14), i.e. a calcified lesion (14) present on the vascular tissue (12) of a host. In the subject methods, the local environment of the lesion (14) is maintained at a sub-physiologic pH for a period of time sufficient for the mineral content of the lesion to be reduced, e.g. by flushing the lesion (14) with a fluid capable of locally increasing the proton concentration in the region of the lesion (14). Also provided are systems and kits for practicing the subject methods. The subject methods, and devices find particular use in the treatment of vascular diseases associated with the presence of calcified lesions (14) an vascular tissue (12).
Clinical and mechanistic studies have shown that a hyperglycaemic metabolic condition is associated with a higher incidence of infection and consecutive increased morbidity and mortality. The underlying mechanisms in detail are not completely understood. So far it is not clear whether systemic increased glucose levels are caused by a stress reaction of the body through a catabolic metabolism situation as well as a "stress-induced insulin resistance", or infections are promoted by hyperglycemia. From in vivo and in vitro studies, a glucose threshold for the lung is known (147 mg / dL), similar to that in the kidney. It can be hypothesized, that an intra-alveolar glucose in turn promotes bacterial growth as a nutrient substrate. The aim of the study is to determine the concentration of glucose in the alveolar space in connection with hyperglycemic conditions, and to demonstrate a higher incidence of pneumonia in this patient group. The study will enroll cardiac surgery patients receiving surgical treatment and expected postoperative ventilation. Systemic blood glucose monitoring is recorded throughout hospitalization, as well as the removal of bronchial aspirates intraoperatively and during ventilation to measure glucose levels and bacterial levels. The incidence of pneumonia is recorded during the postoperative period by means of radiological examinations and / or microbiological examinations.
PURPOSE:To provide a matrix preparation composed of a fish-growth hormone and an enteric polymer and capable of oral administration. CONSTITUTION:A fish-growth hormone composed of a polypeptide containing 180-190 amino acid residues and having about 20000-30000 molecular weight and an enteric polymer are dissolved in ammonia water and the resultant solution is frozen at -70--20 deg.C under a reduced or ordinary pressure and subsequently dried at -10--40 deg.C under vacuum to obtain the objective matrix preparation. As the fish hormone, e.g. a material extracted from the hypophysis of a salmon, an eel, etc., or a material obtained by using the recombinant DNA technique is used. As the enteric polymer, hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, methacrylic acid copolymer L, methacrylic acid copolymer S, etc., is used. The content of the fish-growth hormone is 1-20mg per 100mg preparation and the enteric polymer is used in an amount of >=5 times the amount of the fish-growth hormone.
A patch for active substance transdermal delivery comprises at least one surface acoustic wave transducer comprising one or more electrodes 804 on a piezoelectric layer 803, and an active substance-infused layer 805 adjacent the piezoelectric layer or separated therefrom by an intermediate layer (902, Fig.9). There may be dressing 802 and protective 806 layers. The electrodes are located over the active substance infused layer such that, when the patch is on skin and the transducers energised, acoustic energy causes active substance molecule transfer through the skin. Acoustic energy temporarily disrupts the epidermal impervious layer creating micropores and is assisted by turbulence in the acoustic wave, local heating, internal streaming in the infused layer and increases in local pressure induced by the waves. Microneedles may also be provided. The electrodes may be linear or, preferably, circular interdigitating electrodes to focus acoustic energy to increase substance transfer. There may be a wired or wireless controller and the electrodes may be powered by a battery or an energy receiving antenna on the piezoelectric layer. Piezo layer strain relieving apertures (705, Fig. 7) prevent electrode flexing damage.